Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

The role of tissue microarrays in prostate cancer biomarker discovery.

Datta MW, True LD, Nelson PS, Amin MB.

Adv Anat Pathol. 2007 Nov;14(6):408-18. Review.

PMID:
18049130
2.

A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.

Camp RL, Neumeister V, Rimm DL.

J Clin Oncol. 2008 Dec 1;26(34):5630-7. doi: 10.1200/JCO.2008.17.3567. Epub 2008 Oct 20. Review.

PMID:
18936473
3.

[Tissue microarrays. High-throughput procedures to verify potential biomarkers].

Kuefer R, Hofer MD, Gschwend JE, Rubin MA.

Urologe A. 2004 Jun;43(6):659-67. Review. German.

PMID:
15107975
4.

Discovery of prostate cancer biomarkers by microarray gene expression profiling.

Sørensen KD, Ørntoft TF.

Expert Rev Mol Diagn. 2010 Jan;10(1):49-64. doi: 10.1586/erm.09.74. Review.

PMID:
20014922
5.

From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer.

Schlomm T, Chun FKh, Erbersdobler A.

Methods Mol Biol. 2010;664:177-89. doi: 10.1007/978-1-60761-806-5_17.

PMID:
20690063
6.

Tissue microarrays: applications in urological cancer research.

Merseburger AS, Anastasiadis AG, Hennenlotter J, Schilling D, Simon P, Machtens SA, Serth J, Stenzl A, Kuczyk MA.

World J Urol. 2006 Nov;24(5):579-84. Epub 2006 Aug 9. Review.

PMID:
16896596
7.

Pan-cadherin as a high level phenotypic biomarker for prostate cancer.

Wehbi NK, Dugger AL, Bonner RB, Pitha JV, Hurst RE, Hemstreet GP 3rd.

J Urol. 2002 May;167(5):2215-21.

PMID:
11956481
8.

Cross-platform method for identifying candidate network biomarkers for prostate cancer.

Jin G, Zhou X, Cui K, Zhang XS, Chen L, Wong ST.

IET Syst Biol. 2009 Nov;3(6):505-12. doi: 10.1049/iet-syb.2008.0168.

PMID:
19947776
9.

Multiple biomarker tissue microarrays: bioinformatics and practical approaches.

Bentzen SM, Buffa FM, Wilson GD.

Cancer Metastasis Rev. 2008 Sep;27(3):481-94. doi: 10.1007/s10555-008-9145-8. Review.

PMID:
18437294
10.

Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer.

Teng YH, Tan PH, Chia SJ, Zam NA, Lau WK, Cheng CW, Bay BH, Yip GW.

Mod Pathol. 2008 Jul;21(7):893-901. doi: 10.1038/modpathol.2008.70. Epub 2008 May 16.

11.

Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.

Mucci NR, Akdas G, Manely S, Rubin MA.

Hum Pathol. 2000 Apr;31(4):406-14. Erratum in: Hum Pathol 2000 Jun;31(6):778.

PMID:
10821485
12.

Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays.

Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P.

Hum Pathol. 2004 Mar;35(3):357-66.

PMID:
15017593
13.

High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.

Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.

PMID:
22473923
14.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

15.

hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.

Lapointe J, Malhotra S, Higgins JP, Bair E, Thompson M, Salari K, Giacomini CP, Ferrari M, Montgomery K, Tibshirani R, van de Rijn M, Brooks JD, Pollack JR.

Am J Surg Pathol. 2008 Feb;32(2):205-9. doi: 10.1097/PAS.0b013e318124a865.

PMID:
18223322
16.

Tissue microarrays: applications in genomic research.

Watanabe A, Cornelison R, Hostetter G.

Expert Rev Mol Diagn. 2005 Mar;5(2):171-81. Review.

PMID:
15833047
17.

[Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].

Ohori M.

Gan To Kagaku Ryoho. 2009 Jan;36(1):6-10. Review. Japanese.

PMID:
19151558
18.

ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML.

Neoplasia. 2006 Apr;8(4):319-29.

19.

SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation.

Heebøll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjøt L, Orntoft TF, Tørring N.

Histol Histopathol. 2008 Sep;23(9):1069-76.

PMID:
18581278
20.

[Organization of data and tissue banks for new prognostic factors in adenocarcinoma of the prostate. An interdisciplinary uropathologic approach].

Burger M, Hartmann A, Stoehr R, Hofstaedter F, Kneitz B, Riedmiller H, Wieland WF, Denzinger S.

Urologe A. 2007 Sep;46(9):1094. German. No abstract available.

PMID:
17628773
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk